FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management

FDA Assigned PDUFA Goal Date of April 30, 2019 FDA Not Currently Planning Advisory Committee Meeting for NDA SAN DIEGO, Dec. 31, 2018 -- (Healthcare Sales & Marketing Network) -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnol... Biopharmaceuticals, Surgery, FDA Heron Therapeutics, postoperative pain, bupivacaine, meloxicam
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news